
Conference Coverage
about 17 hours ago
ICYMI: Highlights From the 2025 ASPC Congress on CVD Prevention4 days ago
ICYMI: Highlights From AACR 2025Latest Content

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Advancements in 2025 in non-Hodgkin lymphoma treatments focused on bringing CAR T-cell therapy and bispecific antibodies into the community setting.

The meeting included new evidence and expert insights on hormone therapy, AI, and the expanding role of GLP-1 therapies in cardiovascular care.

A study using Mendelian randomization found higher BMI and IBD have causal links to hidradenitis suppurativa risk.

Rucaparib’s full approval for BRCA-mutated mCRPC is supported by data showing significant gains in radiographic progression-free survival.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

A last-minute push to extend Affordable Care Act subsidies was stopped as GOP leadership prevented an expedited vote, leaving the future of the subsidies uncertain.

These were the most-read articles on alopecia areata in 2025.

Twice-yearly depemokimab cuts asthma exacerbations in phase 3 trials for patients aged 12 and older with severe eosinophilic asthma.

Medicaid’s Institution for Mental Diseases (IMD) rule bars federal funding for psychiatric facilities with more than 16 beds, but findings indicate that state waivers allowing treatment of serious mental illness in IMDs do not increase overall psychiatric hospitalizations.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.


























































